FDA Approves Four Neurological Drugs Targeting Alzheimer's, Glioma, and Rare Disease
A roundup of recent FDA brain-health approvals including lecanemab's full Alzheimer's approval and a new glioma drug.
Summary
The FDA has approved several significant neurological therapies in recent months. Leqembi (lecanemab) received full traditional approval for early Alzheimer's disease in patients with confirmed amyloid pathology, upgrading from its earlier accelerated status. Kisunla (donanemab) also gained approval for Alzheimer's with a revised dosing schedule. Dordaviprone (Modeyso) received accelerated approval for diffuse midline glioma with an H3 K27M mutation in patients whose disease progressed after prior therapy. Additionally, Avlayah (tividenofusp alfa) was approved for neurologic manifestations of Hunter syndrome in pediatric patients. Together, these approvals represent meaningful advances across Alzheimer's disease, rare pediatric neurological conditions, and aggressive brain tumors, signaling an active period for FDA neurology decisions.
Detailed Summary
The FDA has been notably active in the neurological and brain-health space over recent months, granting approvals across Alzheimer's disease, rare pediatric disorders, and malignant brain tumors. These decisions reflect years of clinical development and mark important milestones for patients with limited treatment options.
Leqembi (lecanemab-irmb), developed by Eisai and Biogen, received full traditional FDA approval for early Alzheimer's disease — specifically for patients with mild cognitive impairment or mild dementia with confirmed amyloid-beta pathology. This upgrade from accelerated to full approval was based on demonstrated clinical benefit in slowing cognitive decline, not merely surrogate biomarker endpoints. It represents a landmark moment for the amyloid-targeting hypothesis in Alzheimer's research.
Kisunla (donanemab), Eli Lilly's anti-amyloid antibody, also holds FDA approval for Alzheimer's disease. A revised titration dosing schedule was approved in 2025 to improve tolerability and safety management in patients with mild cognitive impairment or mild dementia, addressing real-world clinical concerns around amyloid-related imaging abnormalities (ARIA).
Dordaviprone (Modeyso) received accelerated approval for diffuse midline glioma harboring an H3 K27M mutation — a rare but devastating pediatric and adult brain cancer with very poor prognosis. Approval covers patients aged one year and older with progressive disease following prior therapy, offering a targeted option where few exist.
Avlayah (tividenofusp alfa-eknm) was approved for the neurologic manifestations of Hunter syndrome (MPS II) in pediatric patients under accelerated approval, based on reductions in cerebrospinal fluid heparan sulfate as a surrogate endpoint.
Caveats include that several of these approvals are accelerated, meaning confirmatory trials are still ongoing. Clinicians should monitor post-marketing data closely, particularly for ARIA risks with anti-amyloid therapies.
Key Findings
- Lecanemab (Leqembi) received full FDA approval for early Alzheimer's, confirming clinical benefit beyond amyloid reduction.
- Donanemab (Kisunla) gained a revised dosing schedule to improve safety management of ARIA in Alzheimer's patients.
- Dordaviprone (Modeyso) approved for H3 K27M-mutant diffuse midline glioma in patients aged 1 year and older.
- Avlayah approved for neurologic Hunter syndrome manifestations in pediatric patients via accelerated pathway.
- Multiple approvals rely on surrogate biomarker endpoints; confirmatory clinical outcome data are still pending.
Methodology
This summary is based on FDA approval announcements and regulatory summaries rather than a primary clinical trial publication. Approvals were granted through both traditional and accelerated pathways, with the latter requiring post-marketing confirmatory trials to verify clinical benefit.
Study Limitations
This summary is based on a secondary FDA news digest rather than original approval documents or trial publications; full prescribing information and trial data should be reviewed before clinical application. Several approvals are accelerated, meaning long-term clinical benefit has not yet been fully confirmed. No approvals were specifically dated within the two-week window ending May 5, 2026.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.